LAUSR

Dear Editor, Vaccination against SARS-CoV-2 is particularly important for patients with systemic lupus erythematosus (SLE), who may be at increased risk of hospitalization from COVID-19 [1]. However, the most common reason for vaccine refusal is fear of SLE flare [2]. While SARS-CoV-2 mRNA vaccines could potentially induce interferon production and increase SLE activity [3], it is unclear if SARSCoV-2 vaccines are poorly tolerated in SLE. In March 2021, we surveyed 466 SLE outpatients from a Rheumatology Division in New York City. SLE was defined using ICD-10 algorithms. Patients reported adverse events (AE) within 7 days of vaccination. Separately, patients reported “typical” disease flares within two weeks of vaccination. The study was approved by Hospital for Special Surgery Institutional Review Board. 183 patients with SLE responded (39.3%);mean age 52.5 [SD 14.2] years; 94% female; 65.6%; White 15.9%; Hispanic/Latinx. 136 (74.3%) reported SARs-CoV-2 vaccination. Eighty-one (59.6%) received Pfizer, 48 (39.3%) received Moderna, (72/129 received both doses) and 4 (2.9%) received Janssen. Three vaccines manufacturers were unidentified. One hundred patients (74%) reported AEs: 61% after the first dose and 71% after the second. Most common were pain at injection site (54%), fatigue (45%), headache (36%), sore shoulder (34%), and muscle aches (26%) (Supplement). No patients reported anaphylactic symptoms. Eleven patients (8.1%) reported flares (Table 1). These patients were older (59.8 [14.3] versus 54.2 [13.9] years) and more likely to be White (90.9% versus 65.6%). Only 1 patient who flared reported previous suspected/confirmed COVID-19 (9.1% vs. 8% in the non-flare group). Flares occurred in 12.5% receiving Moderna (N = 6) and 6.2% receiving Pfizer (N = 5); 1/7 patients who received both doses flared both times (Table 1). Of 12 total flares, 8 occurred after the first dose and 4 after the second. Medications to prevent or treat side effects were used by both flare and non-flare groups (Supplement). Most flares after the first dose were “mild” (87.5%), whereas most after the second were “moderate” (75%). Only one flare, after the 1st dose, was severe and characterized by joint pain and brain fog, lasting 20 days (Table 1). Six of 12 flares started 1 day after vaccination, 4/12 started 4–7 days later, and none started > 7 days later. Most flares resolved within 7 days; however, 3/12 lasted 8–21 days and 2/12 lasted > 21 days. We acknowledge possible misclassification of AEs as flares in the absence of confirmatory laboratory studies. However, we specifically asked patients to report symptoms concordant with their typical flares, separately from AEs. Although 100 patients reported AEs, only 11 reported a flare. This method for identifying flares is supported by data showing that SLE patients are reliable narrators of their disease experience and that self-reported SLE flares are associated with clinically meaningful outcomes [4, 5]. Given that the majority of patients reported AEs, whereas few reported flares, it does not appear that side effects alone explain our results. To prevent over interpretation of these data, we did not perform statistical testing. * Medha Barbhaiya [email protected]